Obesity Rates
4 articles on Obesity Rates, written by Shotlee and medically reviewed for clinical accuracy.
Seoul Hoards 66% of GLP-1 Supply as High-Risk Areas Lack
Two-thirds of South Korea's GLP-1 obesity drugs, including Wegovy and Mounjaro, flow to Greater Seoul despite higher obesity rates elsewhere. This supply imbalance raises alarms over access for high-risk patients. Data reveals stark regional disparities in distribution.
2 min read
America's Most Obese States Unveiled: How Ozempic is Reshaping the Landscape
A recent report highlights the states with the highest obesity rates and analyzes the increasing use of GLP-1 medications such as Ozempic. The data reveals regional trends and potential impacts on public health, with higher usage in the South, Midwest, and Appalachia.
3 min read
US Obesity Rates Decline: Are GLP-1 Drugs Like Ozempic & Wegovy the Answer?
New data reveals a drop in US obesity rates, and GLP-1 drugs like Ozempic and Wegovy are likely playing a significant role. This post explores the impact of these medications and what it means for your health.
4 min read
GLP-1 Weight Loss Drugs and the Decline in Obesity: What You Need to Know
New data reveals a drop in obesity rates alongside increased use of GLP-1 weight-loss drugs. This blog explores the connection, offers actionable insights, and discusses the implications for your health and wellness journey.
4 min read